---
title: "Nurtec ODT (rimegepant), all indications: Pharmacology questions"
description: "Pharmacology questions on Nurtec ODT (rimegepant) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Mechanism, Pharmacokinetics, and Components. Questions: How does Nurtec ODT work (mechanism of action)? How is Nurtec ODT metabolized and eliminated? How long does Nurtec ODT stay in your system (half-life)? How fast is Nurtec ODT absorbed (time to peak concentration)? 1 further question follow. 5 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/nurtec-odt/pharmacology"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Nurtec ODT (rimegepant), all indications: Pharmacology questions

Manufacturer: Pfizer Inc  
Prescribing information: [Nurtec ODT](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036)  
Indication pages: [Acute treatment of migraine](https://www.evicenter.com/medical-information/nurtec-odt--acute-treatment-of-migraine)

## Mechanism

<a id="nurtec-mechanism"></a>

### How does Nurtec ODT work (mechanism of action)?

> “Rimegepant is a calcitonin gene-related peptide receptor antagonist.”

Source: [NURTEC ODT: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036#:~:text=Rimegepant%20is%20a%20calcitonin%20gene%2Drelated%20peptide%20receptor%20antagonist.)

> “The relationship between pharmacodynamic activity and the mechanism(s) by which rimegepant exerts its clinical effects is unknown.”

Source: [NURTEC ODT: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036#:~:text=The%20relationship%20between%20pharmacodynamic%20activity,its%20clinical%20effects%20is%20unknown.)

> “CGRP is a pain-signaling neuropeptide released by the trigeminal nerve<sup>1-6</sup>
> CGRP levels are elevated during a migraine attack. The activation of CGRP receptors may lead to:
> Vasodilation
> Inflammation
> Pain signaling”

Source: [NURTEC ODT: MOA | NURTEC® ODT (rimegepant) | For HCPs | Risk Info, captured 2026-11-13](https://nurtec.pfizerpro.com/moa#:~:text=CGRP%20is%20a%20pain%2Dsignaling%20neuropeptide,Pain%20signaling)

## Pharmacokinetics

<a id="nurtec-metabolism"></a>

### How is Nurtec ODT metabolized and eliminated?

> “Rimegepant is primarily metabolized by CYP3A4 and to a lesser extent by CYP2C9. Rimegepant is the primary form (~77%) with no major metabolites (i.e., >10%) detected in plasma.”

Source: [NURTEC ODT: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036#:~:text=Rimegepant%20is%20primarily%20metabolized%20by,%28i.e.%2C%20%3E10%25%29%20detected%20in%20plasma.)

> “Following oral administration of [14C]-rimegepant to healthy male subjects, 78% of the total radioactivity was recovered in feces and 24% in urine. Unchanged rimegepant is the major single component in excreted feces (42%) and urine (51%).”

Source: [NURTEC ODT: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036#:~:text=Following%20oral%20administration%20of%20%5B14C%5D%2Drimegepant,feces%20%2842%25%29%20and%20urine%20%2851%25%29.)

> “Since the contribution of CYP2C9 to rimegepant metabolism is considered minor, CYP2C9 polymorphism is not expected to significantly affect its exposure.”

Source: [NURTEC ODT: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036#:~:text=Since%20the%20contribution%20of%20CYP2C9,to%20significantly%20affect%20its%20exposure.)

<a id="nurtec-half-life"></a>

### How long does Nurtec ODT stay in your system (half-life)?

> “The elimination half-life of rimegepant is approximately 11 hours in healthy subjects.”

Source: [NURTEC ODT: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036#:~:text=The%20elimination%20half%2Dlife%20of%20rimegepant%20is%20approximately%2011%20hours%20in%20healthy%20subjects.)

<a id="nurtec-onset-absorption"></a>

### How fast is Nurtec ODT absorbed (time to peak concentration)?

> “Following oral administration of NURTEC ODT, rimegepant is absorbed with the maximum concentration at 1.5 hours. The absolute oral bioavailability of rimegepant is approximately 64%.”

Source: [NURTEC ODT: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036#:~:text=Following%20oral%20administration%20of%20NURTEC,of%20rimegepant%20is%20approximately%2064%25.)

## Components

<a id="nurtec-inactive-ingredients"></a>

### What are the inactive ingredients in Nurtec ODT?

> “NURTEC ODT (orally disintegrating tablets) is for sublingual or oral use and contains 85.7 mg rimegepant sulfate, equivalent to 75 mg rimegepant free base, and the following inactive ingredients: benzyl alcohol, eucalyptol, gelatin, limonene, mannitol, menthol, menthone, menthyl acetate, sucralose, and vanillin.”

Source: [NURTEC ODT: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036#:~:text=NURTEC%20ODT%20%28orally%20disintegrating%20tablets%29,menthyl%20acetate%2C%20sucralose%2C%20and%20vanillin.)

## Related pages
- [Medical information: Nurtec ODT (rimegepant): All indications](https://www.evicenter.com/medical-information/nurtec-odt)
- [Indication](https://www.evicenter.com/medical-information/nurtec-odt/indication)
- [Safety](https://www.evicenter.com/medical-information/nurtec-odt/safety)
- [Specific populations](https://www.evicenter.com/medical-information/nurtec-odt/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/nurtec-odt/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/nurtec-odt/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/nurtec-odt/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/nurtec-odt/access-and-coverage)
